Aubagio and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Aubagio (teriflunomide), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Ampyra, and have Relapsing-remitting multiple sclerosis.

The study is created by eHealthMe based on reports of 49,894 people who have side effects when taking Aubagio from the FDA, and is updated regularly.

What is Aubagio?

Aubagio has active ingredients of teriflunomide. It is often used in multiple sclerosis. eHealthMe is studying from 50,041 Aubagio users. Check the latest studies of Aubagio.

On Aug, 06, 2026

49,894 people reported to have side effects when taking Aubagio.
Among them, 316 people (0.63%) died.

Among these 316 people:

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aubagio:

Aubagio (50,041 reports)

Expand to all the drugs that have ingredients of teriflunomide:

Death and drugs with ingredients of teriflunomide (304 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Aubagio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,115 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on teriflunomide (the active ingredients of Aubagio) and Aubagio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Aubagio and Death - a phase IV clinical study of FDA data

Summary:

What is Aubagio?

Among these 316 people:

How long have people been on Aubagio when they died? *

What is the gender of people who died when taking Aubagio? *

What is the age of people who died when taking Aubagio? *

What are other drugs people take besides Aubagio? *

What are other side effects people have before they died? *

What are the existing conditions these people have? *